The Lonza CEO said the company is not under any pressure to exit the Capsules and Health Ingredients (CHI) business and is ...

Lotte Biologics has ambitious plans for its antibody-drug conjugate and contract development and manufacturing organization ...

SEOUL, Dec. 17 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical company, said Tuesday it has established a new subsidiary to specialize in the contract development and ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

By 2030, we aim to record 1.5 trillion won ($1.04 billion) in CDMO business," Chairman Seo Jung-jin said during a press conference Tuesday. The new company will be led by Lee Hyuk-jae, Celltrion's ...

Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Electronic Chemicals CDMO & CRO Market by Type, Scale, Application, End-Use & Region-Global Forecast to 2029" report has been added to ...

Scinai Immunotherapeutics, which focuses on developing inflammation and immunology biological products and providing CDMO services through its Scinai Bioservices business unit, established a U.S ...

The streamlined organizational model, operational by Q2 2025 ... the decision to divest its CHI business and reorganize the CDMO business “rids Lonza of the main drag” and “creates a ...

The new subsidiary, incorporated in Delaware, will operate under the name Scinai Bioservices Inc. In 2024, Scinai launched its CDMO business unit, branded as Scinai Bioservices, operating from the ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to funds managed by GHO Capital Partners LLP ...